Fumaric (few-mare-ic) acid esters: This may be a treatment option for patients who have psoriasis and multiple sclerosis (MS). This medicine is FDA-approved to treat relapsing forms of MS in adults.

Apremilast is a newer medicine that provides strong treatment for plaque psoriasis and psoriatic arthritis. Unlike other strong medicines for psoriasis, you do not need to have medical tests while ...

Topical corticosteroids remain the most widely prescribed medications for plaque psoriasis. These range in strength from weak, over-the-counter steroids such as 1% hydrocortisone to superpotent ...

Treatment with risankizumab following inadequate response to secukinumab or ixekizumab was associated with improved disease severity, quality of life, and symptoms among patients with plaque psoriasis ...

Canadian College of Naturopathic Medicine, 2004). The purpose of this article is to (a) highlight the current use of herbal remedies in the treatment of psoriasis; (b) review the existing ...

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

SAR-441566 is under clinical development by Sanofi and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris ...

Tapinarof cream 1%, a novel nonsteroidal aryl hydrocarbon receptor agonist, has emerged as a promising solution for plaque psoriasis. In the PSOARING 1 and PSOARING 2 phase 3 trials, tapinarof ...

Improved Psoriasis Area and Severity Index scores and decreased rates of adverse events, serious adverse events, and discontinuations were observed through 3 years of continuous deucravacitinib ...

No clinically meaningful differences were observed in the efficacy, safety, pharmacokinetics, and immunogenicity of proposed biosimilar and ustekinumab for the treatment of moderate to severe plaque ...

“The idea is to identify psoriasis patients that are destined to develop psoriatic arthritis,” she said. Besides that, identifying biomarkers is key to advancing personalized medicine for ...